What medication should be prescribed for an adolescent with mild-to-moderate anxiety expected to last only a few weeks?

Recommendation for Mild-to-Moderate Anxiety in Adolescents (Short Duration)

For mild-to-moderate anxiety symptoms expected to last only a few weeks in adolescents, cognitive behavioral therapy (CBT) should be the first-line treatment rather than medication, as SSRIs require 6-12 weeks to achieve clinically meaningful benefit and are not appropriate for short-term symptom management. 1

Why Medication is Not Appropriate for Short-Term Anxiety

The pharmacodynamic profile of SSRIs—the only evidence-based medication class for adolescent anxiety—fundamentally mismatches the clinical scenario:

• SSRIs show clinically significant improvement only by week 6, with maximal benefit at week 12 or later 1
• For symptoms expected to resolve within "a few weeks," the anxiety would likely improve naturally before medication could provide therapeutic benefit
• Starting an SSRI commits the patient to at least 12 weeks of treatment to assess full response, which extends far beyond the anticipated symptom duration

The SSRI Timeline Problem

The logarithmic response model for SSRIs demonstrates 1:

• Week 0-2: Only statistically (not clinically) significant improvement
• Week 6: First clinically meaningful improvement
• Week 12+: Maximal therapeutic effect

This timeline makes SSRIs inappropriate for short-term anxiety management in adolescents.

Benzodiazepines Are Not Recommended

While benzodiazepines provide rapid symptom relief, they are not recommended for adolescent anxiety disorders based on current evidence:

• The 2020 AACAP guidelines 1 do not recommend benzodiazepines for pediatric anxiety disorders
• One older study 2 from 1990 mentioned benzodiazepines, but this predates current evidence standards
• Recent data shows increasing concerns about benzodiazepine prescribing in young adults, including dependency issues 3
• No high-quality RCT evidence supports benzodiazepine use in adolescent anxiety

Recommended Approach

Start with CBT as monotherapy for this clinical scenario:

• CBT is first-line psychotherapy with strong evidence 1, 4
• Provides skills that extend beyond symptom resolution
• No medication-related adverse effects or monitoring requirements
• No discontinuation syndrome concerns

If Symptoms Persist Beyond 4-6 Weeks

Only if anxiety symptoms worsen or persist beyond the expected short duration should you consider:

1. Reassess the diagnosis—persistent symptoms may indicate a chronic anxiety disorder rather than transient stress
2. Consider SSRI initiation if criteria for GAD, social anxiety, separation anxiety, or panic disorder are met 1
3. Combination CBT + SSRI shows superior efficacy (NNT 2.8-9.3) compared to either alone 1, 5

SSRI Selection (If Needed)

When medication becomes appropriate 1:

• Sertraline or fluoxetine are reasonable first choices based on evidence 1, 6, 7
• Start with subtherapeutic "test" dose to assess for behavioral activation
• Titrate slowly at 1-2 week intervals for shorter half-life SSRIs (sertraline, citalopram)
• Monitor closely for suicidality, especially first month and after dose changes (NNH = 143) 1

Critical Safety Considerations

If SSRIs are eventually prescribed 1:

• Black box warning for suicidal thinking/behavior through age 24
• Behavioral activation (restlessness, agitation, impulsiveness) occurs more commonly in younger patients—requires slow titration and close monitoring
• Discontinuation syndrome can occur with shorter-acting SSRIs (paroxetine, fluvoxamine, sertraline)
• Parental oversight of medication regimens is paramount

Common Pitfall to Avoid

Do not prescribe SSRIs for anxiety symptoms expected to be short-term. The medication timeline does not align with the clinical presentation, and you risk exposing the patient to unnecessary adverse effects, monitoring burden, and a 12+ week medication trial for a self-limited condition.